bpc 157 kpv + Combo FDA panel backs compounded BPC-157,

Since traditional chemotherapy treatment of metastatic melanoma is not very effective, MC1R targeting peptide-drugs are highly desired (Helmbach et al., 2001)

Personally, I believe common sense tells us that 'Megadoses' should still be avoided

Frequency: Once weekly on a consistent day

Enter the total peptide content of your vial (in mg or mcg), the volume of bacteriostatic water you plan to add, and your target dose

Track the number of doses used to know when replacement is needed

Also of interest is the observation that mouse models of ALD do not develop cerebral inflammation, but most resemble the non-inflammatory myeloneuropathic phenotype (Pujol et al., 2002)